

**Basingstoke, Southampton and Winchester  
District Prescribing Committee (DPC)**

**Recommendations of the meeting of 12<sup>th</sup> April 2016**

**Supported or limited support e.g. Specialist recommendation**

- **Chronic non-malignant pain guidelines** – These were approved for use and are available on the guidelines section of the West Hampshire CCG website (see links below).
- **Osteoporosis Guidelines – Medical Management of Men and Women who have (or are at risk of) Osteoporosis** – These updated guidelines were approved and are available on the guidelines section of the West Hampshire CCG website.
- **High Strength Beclomethasone dipropionate/Formoterol fumarate (Fostair®) 200/6 MDI and DPI (NEXThaler®)** – The DPC approved the use of this high strength corticosteroid/LABA combination inhaler for use in Adult Asthma patients only.

NB the Fostair 100/6 NEXThaler was also approved for use in Asthma and COPD and will be added as an option in the COPD guidelines in due course when they are updated. (Fostair 100/6 MDI already included)

**Not supported**

- **Fentanyl Iontophoretic transdermal system (Ionsys®)**- the DPC did not support the use of this locally as it offers no real benefit over current options and would be at greater cost.
- **Nortriptyline** – Following an evaluation of the latest evidence the DPC agreed that Nortriptyline should no longer be recommended as an alternative to amitriptyline (first line) for neuropathic pain. If an alternative is required then Imipramine should be considered based on evidence and cost. The local Chronic pain services will be consulted on this decision.

**Other Information / Reminders**

- **Hospital only drugs on GP clinical system** – The final Guidance document detailing a 'list of high risk medicines' and how to record them on GP systems has been signed off by the Hampshire Medicines Safety Group and will be available on the guidelines section of the West Hampshire CCG website shortly (see links below).
- **Managing Behaviour problems in Patients with dementia** - Southern health (Mental health Guidelines and Formulary Committee) have recently approved these guidelines and are available at [here](#)
- **Rosuvastatin (Crestor®)**- Following an evaluation of the latest evidence the DPC agreed not to support the widespread use of Rosuvastatin however it did recognise there may be a small number of occasions where its use is appropriate, The DPC will issue a position statement in due course.

➤ DPC summaries are available at:

<http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/district-prescribing-committee>

Guidance documents are available at:

<http://www.westhampshireccg.nhs.uk/downloads/categories/medicines/guidance>

**Summarised on behalf of the District Prescribing Committee - Andrea White (Southampton City CCG)**

**15/04/16**